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Summary A method of epitope analysis is described in which the binding of one monoclonal antibody
(MAb) to radiolabelled carcinoembryonic antigen (CEA) competes with the subsequent binding of an
immobilised second MAb. From the degree of blocking obtained, we have identified both structurally related
and independent epitopes on CEA. Using this technique to study fifteen MAbs, we have been able to
recognise at least 6 unrelated epitopes of the CEA glycoprotein.
Further characterisation of these epitopes was accomplished by means of immunohistochemistry. Of the
fifteen MAbs, 6 were specific for CEA and reacted with at least 3 unrelated regions of the glycoprotein. Of
the remaining 9 MAbs, 2 cross-reacted with erythrocytes, 5 with components of liver and 7 with
polymorphonuclear neutrophils. Cross-reactions with liver were varied showing differential antibody specifi-
city for bile canaliculi, Kupffer cells and bile duct epithelium. A high degree of correlation between epitope
relatedness and immunohistochemical specificity was found. Two CEA-specific and 4 cross-reactive MAbs
were also shown to react with ion-sensitive sites on the CEA glycoprotein.
Carcinoembryonic antigen (CEA), first described by
Gold & Freedman (1965), is the most widely
studied tumour marker. Antibodies against this
antigen have proved to be of clinical value in the
radioimmunoassay of human circulating CEA
(Neville & Cooper, 1976) and also for the location
of tumours using the technique of radio-immuno-
localisation (RIL) (Begent, 1985).
CEA is immunologically a complex macro-
molecule expressing both protein and carbohydrate
determinants (Rogers, 1983). Extensive studies with
polyclonal and monoclonal antibodies have demon-
strated two broad groups of specificity; those
attributed to epitopes which are unique to CEA
and those which are also expressed on other glyco-
proteins (Primus et al., 1983). Of the many cross-
reactions which have been reported, the most
extensively studied are ascribed to the CEA-like
antigens - NCA-1 (Von Kleist et al., 1972), NCA-2
(Burtin et al., 1973) and normal biliary glycoprotein
(Svenberg, 1976). Cross-reactions with circulating
cells (Dillman et al., 1984) and with components of
liver, as demonstrated by immunohistochemical
techniques, however, have been less well character-
ised yet these reactions may give rise to non-specific
accumulation of antibodies resulting in higher-
backgrounds in RIL studies.
Monoclonal antibodies (MAbs) are particularly
useful reagents for studying the detailed antigenic
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expression of CEA. Moreover, since they bind to
discrete structures (epitopes) on the CEA molecule,
they can be selected for reactivity with the CEA-
specific regions of the glycoprotein.
In order to select monoclonal antibodies for
clinical assessment, it is important to characterise
the relatedness and tissue specificity of the epitopes
that they recognise. In this paper, we describe the
combined use of epitope analysis, binding studies
and immunohistochemistry to map distinct regions
of the CEA glycoprotein and identify potentially
useful antibodies.
Materials and methods
Purified CEA was prepared from metastases of
colonic tumour as previously described (Rogers et
al., 1983). Radio-iodination to a specific activity of
6pCipg -1 was carried out by the iodogen method
(Fraker & Speck, 1978). Dilution buffer was
prepared as a 0.15M sodium phosphate buffer, pH
7.4, containing 0.1% bovine serum albumin. The
studies at low ionic strength were carried out in
0.02M Tris-HCl buffer at pH 7.4.
Immunisation schedule
Monoclonal antibodies MA/200 and H58 were
raised against purified CEA and HT29 colon
tumour cells respectively as previously described
(Rogers et al., 1983; Rogers et al., 1984). The
remaining 13 MAbs (Table I) were raised against
heat-treated CEA using the following procedure.
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One milligram of purified CEA was heated at 85'C
for 35min in 0.05M phosphate buffer (pH7) at a
concentration of 1 mgml-1. After mixing with 1 ml
of 10% aqueous potassium aluminium sulphate
(alum), the pH was adjusted with constant stirring
to 6.5-7 by dropwise addition of NaOH solution.
After stirring at room temperature for 30min the
resulting precipitate was washed three times in
saline. It was then mixed with 1010 formalised
Bordetella pertussis (kindly supplied by Wellcome
Research Laboratories). Three different immun-
isation schedules were used (see Table I).
Spleen cells from the immunised mice were then
fused with either SP2/0-Ag 14 or P3-NS/1-Ag4-1
myeloma cells (Flow Laboratories, UK) as
previously described (Rogers et al., 1984) and the
hybridomas producing anti-CEA cloned by single
cell transfer.
Preliminary screening
MAb supernatants were screened for the binding to
radiolabelled CEA by double antibody radio-
immunoassay. Eight doubling dilutions of each
MAb supernatant were made in dilution buffer.
Fifty microlitres of each dilution was then mixed
with a further 100p1 of dilution buffer and 50p1 of
125I-labelled CEA. After overnight incubation at
37°C, 50,u1 of a 1:40 dilution of rabbit anti-mouse
antiserum (Dako, Z259) was added together with
50p1 of 10% polyethylene glycol. After a further
3 h incubation at room temperature the immune
precipitate was filtered and counted on an auto-
mated radio-immunoassay machine (Kemtek 3000)
and the percentage binding calculated.
Affinity constants were determined from
inhibition data by the method of Scatchard as
previously described (Rogers et al., 1983).
Inhibition studies were carried out at a dilution of
the antibody previously shown to give 30% of its
maximum binding to radiolabelled CEA. Assays
were set up containing 50pl of MAb at the pre-
determined dilution, 100 p1 of unlabelled CEA over
the concentration range 0-1,000ngml-1 and 50pl
(0.4ng) of labelled CEA. The assay was then com-
pleted as described above. To determine the effect
of low ionic strength on the binding of MAb to
CEA, the above binding studies were performed
using reagents made up in 0.02 M Tris buffer instead
of dilution buffer.
Epitope analysis
The method of epitope analysis adopted in this
study has been designed to determine if saturating
levels of the binding of one MAb to 1251-labelled
CEA blocks the subsequent binding of another
MAb to the same antigen. An outline of the
method is shown in Figure 1. MAbs were tested in
pairs. Oneml of the first antibody supematant was
mixed with 1 ml of cellulose-conjugated donkey
anti-mouse antibody (Wellcome Reagents Ltd.,
UK). The second MAb of each pair (501 of
supernatant) was mixed with 50p1 of 125I-labelled
CEA (0.4ng). After 2h at 37°C, 100p1 aliquots of
each incubation mixture were combined and incu-
bated for an additional 2h at 37°C. The radio-
activity associated with the solid phase was filtered
and washed on the Kemtek 3000 and counted.
High counts in this precipitate indicated that the
MAbs under test bound to independent epitopes.
Table I Immunisation details for the production of MAbs against heat-treated CEA
Time (days) Immunogen Dose (jig) adjuvant route
0 Purified CEA+alum 30 B. Pertussis i.p.
54 Heat-treated CEA in saline 80 i.p.
90 Heat-treated CEA in saline 40 i.s.-
94 Hybridised with SP2/0 myeloma cells
MAbs 1B6, 3H12, 1H12
0 Purified CEA+alum 20 B. Pertussis i.p.
5 Purified CEA+alum 20 i.p.
47 Purified CEA+alum 20 i.p.
100 Heat-treated CEA in saline 17 i.s.-
103 Hybridised with SP2/0 myeloma cells
MAbs F3C1O, F3D9, A5B7, F3E3, E12D4, B4B7
0 Heat-treated CEA+alum 40 B. Pertussis i.p.
41 Heat-treated CEA in saline 40 i.p.
102 Heat-treated CEA in saline 40 i.v.
105 Hybridised with NSI myeloma cells
MAbs lC12, lBl, 2G8, 1H6
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Figure 1 Outline of the binding assay used to deter-
mine epitope relatedness of pairs of monoclonal
antibodies. An excess of the second monoclonal
antibody under test (MAb2) was reacted with 0.4 ng of
iodinated CEA.
Controls were carried out by comparing identical
MAbs in both phases and also by using all MAbs
in both phases. The results were calculated as the
percentage of the maximal binding obtained when
an antibody, directed against a known unrelated
epitope, was used in the fluid phase. Thus theoreti-
cally, 100% represented an unrelated epitope and
0% represented complete or partial structural
similarity of epitopes. The actual percentages,
which fell into two groups, were initially expressed
as a matrix to facilitate the comparison between
antibodies. A binding of >70% indicated inde-
pendent epitopes whereas a binding of <30% indi-
cated that the MAbs recognised chemically related
epitopes.
Immunohistochemical analysis
All studies were performed on formalin-fixed,
paraffin embedded tissues. Sections cut at 4u were
used in conjunction with the indirect immuno-
peroxidase technique. Tissue sections were dewaxed,
and endogenous peroxidase inhibited with 0.3%
hydrogen peroxide in methanol. Sections were then
hydrated and washed twice for 5min with Tris-
buffered saline at pH 7.6 (TBS). The sections were
first bathed for 20min in normal rabbit serum (1:5
in TBS). After draining, the MAbs were applied to
the sections as neat supernatants and left for 1 h in
a moist chamber. After washing with TBS as
above, the sections were incubated with peroxidase-
conjugated rabbit anti-mouse immunoglobulin
(Dako, p161 diluted 1:50 with TBS containing 20%
normal human serum). Sections were washed as
above and then reacted with a freshly filtered
0.6 mgml- 1 solution of diaminobenzidene tetra
HCl (Sigma) in TBS containing 0.03% hydrogen
peroxide. After 6min the sections were washed in
tap water, counterstained with Coles heamatoxylin,
dehydrated, cleared and mounted.
Positive immunohistochemical staining was inter-
preted with reference to control sections in which
the primary antibody was either omitted or
replaced by an unrelated antibody.
In this study a panel of 4 primary colorectal
adenocarcinomas showing varying degrees of differ-
entiation and the adjacent non-neoplastic mucosa
were examined to assess the specific CEA distri-
bution. Cross-reactions of each MAb with
erythrocytes and polymorphonuclear neutrophils
were determined in the tumour sections and in
sections of normal liver, spleen, colon, bone
marrow, and tonsil. Reactions with biliary com-
ponents were assessed on sections of normal liver.
Antibodies which did not show these cross-
reactions but showed a typical CEA staining
pattern were considered to react with CEA-specific
epitopes.
Results
Binding characteristics
Antibody titrations were performed in order to
estimate the amount of CEA bound by each anti-
body at saturation. The MAbs fell into two distinct
patterns. MAbs MA/200, 1C12, 1H6 and 1H12
were capable of binding to almost 80% of the
radiolabelled CEA whereas the remaining MAbs
bound smaller amounts of label, up to -50%. Six
MAbs showed a difference in CEA-binding in low
ionic strength buffer (Figure 2). Of these, MAbs
1 BI and 2G8 showed a significant increase in
binding to labelled CEA in the low ionic strength
buffer whereas MAbs 1C12, B4B7, E112D4 and
MA/200 showed a marked fall in binding capacity
in this buffer. The effect of low ionic strength on
the binding of MAbs 1B1, 2G8, IC12 and MA/200
was reflected in their affinity constants (see Table
II).
Epitope analysis
Each MAb when paired with itself gave a low
percentage of maximal binding of between 0 and
30% showing that each antibody was capable of
self-blocking. The percentage of maximum binding
for other combinations of MAbs were between 0
and 34% for related, and between 70 and 100% for
unrelated antibodies. The complete results for the
fifteen monoclonal antibodies are shown in Figure
3 in which the CEA glycoprotein is schematically
represented and divided into CEA-specific, and the
various cross-reactive regions (see Discussion).
Individual antibodies are represented by the small
bars. These are shown overlapping where the anti-
bodies have been shown to react with related
epitopes. MA/200 was the only exception to this
since it cross-reacted with E12D4, H58 and B4B7
but was unrelated in epitope recognition to IC12.78 P.J. HARWOOD, et al.
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Figure 2 Curves showing the binding of six monoclonal antibodies to iodinated CEA in dilution buffer
(0 O) and in Tris buffer of low ionic strength (0-0).
Table II Binding data and results of immunohistochemical screening for fifteen MAbs against CEA
Affinity (1 mol-1) Immunohistochemical reactions
Ion-sensitive
PBS 0.02M Tris binding site PMNs Erythrocytes Liver CEA-specific
IBI 8.8 x 107 9.1 x 108 Yes -ve -ve -ve Yes
F3E3 ND ND No -ve -ve -ve Yes
lH12 8.4 x 108 8.1 x 108 No -ve -ve -ve Yes
F3C1O ND ND No -ve -ve -ve Yes
F3D9 ND ND No -ve -ve -ve Yes
A5B7 ND ND No -ve -ve -ve Yes
3H12 ND ND No -ve +ve -ve No
1B6 ND ND No -ve +ve -ve No
2G8 3.1 x 108 5.2 x 108 Yes +ve -ve +ve No
E12D4 ND ND Yes +ve -ve +ve No
B4B7 ND ND Yes +ve -ve -ve No
1C12 6.2 x 107 5.7 x 107 Yes +ve -ve +ve No
MA/200 1.3 x 10'0 8.2 x 109 Yes +ve -ve +ve No
1H6 1.6 x 109 1.3 x 109 No +ve -ve -ve No
H58 4.6x 107 4.2x 107 No +ve -ve +ve No
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Figure 3 Schematic representation of specific and cross-reactive regions on CEA. Monoclonal antibody
reactivity is shown by the small bars positioned below the appropriate regions of CEA. Related specificities,
as determined by epitope analyses, are indicated by overlapping the bars. Note the correlation between
epitope relatedness and immunohistochemical specificity.
On the basis of epitope analysis alone, it was
concluded that at least six unrelated regions of the
CEA glycoprotein were capable of reacting with
different groups of monoclonal antibodies (Figure
3). -
Immunohistochemical analysis
The results of the immunohistochemical analyses
are summarised in Table II. All antibodies showed
an anti-CEA 'staining' reaction on sections of colon
tumour which was typified by cell surface and
cytoplasmic staining of malignant glands with more
intense reaction in necrotic debris (Figure 4a). The
MAbs differed mainly in the extent of cross-
reactions with erythrocytes, polymorphonuclear
neutrophils and components of liver. Of the fifteen
MAbs against CEA, 6 did not show any cross-
reactions and were considered to react with CEA-
specific epitopes. Two MAbs, 3H12 and 1B6,
also stained erythrocytes. However, this staining
was weak and was only shown by a small popu-
lation of these cells (Figure 4b). Seven of the anti-
CEA MAbs, MA/200, IC12, E12D4, B4B7, 1H6,
2G8 and H58, however, reacted with polymorpho-
nuclear neutrophils (Figure 4c) and with the
exception of 1H6 and B4B7, they also stained
components of liver (Figure 4d-f). The specificity of
liver staining varied. H58 showed weak staining of
of the bile canaliculi but no staining of either bile
ducts, hepatocytes or Kupffer cells. MA/200,
however, stained bile canaliculi, Kupffer cells and
bile duct epithelium but did not stain hepatocytes.
E12D4 on the other hand, did not stain bile
canaliculi or hepatocytes but did show cytoplasmic
staining of Kupffer cells as well as cell surface
staining of the epithelium of bile ducts. IC12 was
similar to E12D4 except that it did not stain
Kupffer cells. Antibody 2G8, which showed very
weak staining of polymorphonuclear neutrophils,
also stained the cytoplasm of bile duct epithelium
and hepatocytes.
Discussion
The aim of the present work has been to character-
ise monoclonal antibodies against CEA prior to
their evaluation as tumour markers for radio-
immunolocalisation of tumours. In this study we
have raised most of the MAbs against heat-treated
CEA which was mixed with alum and used
formalin-treated Bordetella pertussis as adjuvant.
Our experience suggests that such a procedure gives
a higher proportion of hybridomas producing
CEA-specific antibodies.
Using heat-treated CEA for immunisation, how-
ever, raises the possibility that antibodies may be
directed at artefacts of CEA produced by heat.
Routinely formalin-fixed sections, being exposed to
a temperature of up to 65°C during processing
could give rise to such artefacts. It is unlikely that
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Figure 4 Examples of specific and cross-reactive immunohistochemical reactions. (a) Section of an invasive
adenocarcinoma of the colon with adjacent non-neoplastic mucosa showing a typical specific anti-CEA
reaction. Note that there is positive staining of malighant glands at the cell surface, focally within the
cytoplasm and of the intra-luminal contents ( x 75). (b) Section of normal spleen showing sporadic staining of
erythrocytes within a blood vessel. Note many cells which did not show this cross-reaction ( x 630). (c) Section
of normal spleen showing cross-reactivity with polymorphonuclear neutrophils. Other cell types were negative
( x 400). (d, e, f) Sections of normal liver showing examples of reactions with bile canaliculi (x 750), (d); bile
duct epithelium (x 630), (e); and Kupffer cells (x 630) (f).
our antibodies would recognise such artefacts since
they were initially screened using unheated CEA.
Nevertheless, to confirm this we have compared
formalin-fixed and un-fixed cryostat tissue sections
(Judd & Britten, 1982) of both tumour and normal
tissues which were exposed to temperatures over the
range 37-85°C for up to 8 h. No differences in
either the intensity or distribution of the reaction
was discerned with these sections compared with
controls maintained at room temperature.
Antibodies which cross-react with human
erythrocytes or polymorphonuclear neutrophils
have been shown to be unsuitable for RIL on
account of an increased accumulation in liver and
spleen (Dillman et al., 1984) and possibly a reduced
uptake by tumour. In this study we have investi-
gated these cellular cross-reactions by immunohisto-
chemistry since such cells are widespread in colonic
tumours and may also be present in the normal
tissue sections examined. The epitopes involved in
these reactions are attributed to true cross-reactions
arising from structural similarities with regions of
the CEA glycoprotein since all the MAbs react
strongly with purified CEA. The cross-reactions
noted with erythrocytes, however, were not due to
the known blood group A or precursor H antigen
specificities (Rogers, 1983), since all antibodies were
subjected to an agglutination test to exclude such
antibodies from this study. Reactivity with poly-
morphonuclear neutrophils, on the other hand, is
likely to be due, in part, to normal cross-reacting
antigen (NCA) (Bordes et al., 1975; Burtin &
Fondaneche, 1979). Immunohistochemistry is a
very sensitive method of detecting this antigen and
some antibodies which show a very weak NCA
reaction, like 2G8, may still be useful for local-
isation. In this study seven MAbs reacted with
polymorphonuclear neutrophils, but only two
MAbs, MA/200 and IC12, showed a moderately
strong reaction and were the only two for which
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the NCA reactivity could be reliably quantitated by
radioimmunoassay. Using the latter technique
MA/200 and IC12 gave 9 and 4% cross-reactivity
respectively with purified NCA. Five of the MAbs
which cross-reacted with polymorphonuclear
neutrophils also reacted with components of liver.
However, the differential antibody specificity for
bile canaliculi, Kupffer cells and bile duct epi-
thelium, would suggest that they recognise different
epitopes. Reactivity in liver may be due to biliary
glycoprotein-like cross-reactivity which has been
studied in connection with anti-CEA specificity
(Svenberg, 1976). The differential expression of
these glycoproteins could therefore explain the
staining patterns observed with different MAbs.
Although the method of epitope analysis used in
this study is reproducible, differences in binding
affinity between MAbs could affect the percentage
blocking obtained. To minimise this we have used
saturating amounts of both antibodies in each
assay. The method therefore provides reasonable
evidence about epitope relatedness. The validity of
this approach, however, is further strengthened by
the ability of any given MAb to block itself.
Moreover, there was a high degree of correlation
between epitope relatedness and the immunohisto-
chemical specificity of the antibodies as shown in
Figure 3.
The effect of low ionic strength buffer has been
included in this study to distinguish those anti-
bodies which bind more weakly under normal
physiological conditions and may therefore be less
suitable for localisation (Haskell et al., 1983). Of
the fifteen MAbs, six responded fo a change in the
buffer suggesting that they recognised epitopes
which are sensitive to structural perturbations
brought about by a change in ionic strength. More-
over, we have shown that specific and cross-reactive
epitopes on CEA may be ion-sensitive.
The combined strategy adopted in the present
study, involving epitope analysis and immuno-
histology, has allowed a number of CEA-specific
and cross-reactive antibodies to be identified which
are clearly different in terms of the epitopes which
they recognise. This is important since it provides
an opportunity of using mixtures of different anti-
bodies to overcome possible heterogeneity of CEA
epitope expression within tumours and between
different patients. The six CEA-specific antibodies
obtained in this study, iBi, IH12, F3C1O, F3D9,
F3E3 and A5B7 are currently undergoing further
evaluation for possible use in RIL.
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